Quantumzyme Corp. (OTCQB: QTZM), a computational enzyme engineering firm, announced its participation in the Catalysis and Chemical Engineering Conference (CCE-2026) scheduled for March 9–11, 2026, in Boston, MA. The company plans to showcase how its enzyme engineering platform can transform traditional chemical synthesis, particularly in pharmaceutical manufacturing, by enabling more sustainable and cost-efficient processes.
At the conference, Quantumzyme will highlight recent advancements in green ibuprofen synthesis, focusing on biocatalytic routes that lower environmental impact and production costs. The company will also discuss the expansion of its enzyme platform to high-volume Active Pharmaceutical Ingredients (APIs), including new applications in chiral molecule synthesis using next-generation ketoreductase (KRED) enzymes. These developments are significant for the pharmaceutical and fine-chemical markets, where chiral purity is critical.
Quantumzyme's technology addresses key challenges in current API production, which often relies on legacy chemistries that generate substantial waste and require high solvent usage. The company's biocatalytic pathways aim to reduce waste and solvent consumption, lower carbon intensity, improve process reliability, and support U.S. onshoring and supply-chain resilience for essential medicines. These capabilities position Quantumzyme as a contributor to the broader transformation toward environmentally responsible pharmaceutical manufacturing.
During CCE-2026, Quantumzyme plans to engage with researchers, pharmaceutical manufacturers, process development teams, technology developers, and investors interested in green chemistry and biomanufacturing. The company seeks to explore partnerships that could accelerate the adoption of enzyme-based manufacturing approaches across high-volume API production.
Naveen Kulkarni, CEO of Quantumzyme Corp., stated, "CCE-2026 provides an excellent platform to share our vision for sustainable chemical manufacturing. We look forward to collaborating with global experts and demonstrating how our enzyme engineering technology may offer practical pathways toward cleaner and more efficient production."
Quantumzyme's participation underscores its commitment to advancing next-generation biocatalysis and driving innovation in the pharmaceutical and specialty chemicals industries. For more information, visit the company's website at www.quantumzymecorp.com and its profile on www.otcmarkets.com/stock/QTZM.
